Condition: Relapsed/Refractory Multiple Myeloma · Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd
This is an investigator-initiated, single-center, early-phase clinical study comprising dose escalation and dose expansion phases, designed to evaluate the safety and efficacy of IMV102 in subjects with relapsed/refractory multiple myeloma (RRMM). Eligible subjects will receive an infusion of IMV102 injection. Blood and urine samples will be collected before and after infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety assessments. Tumor response will be evaluated according to the International Myeloma Working Group (IMWG) uniform response criteria (2016). Assessments will be performed at baseline, and then at Day 28 post-infusion, Month 2, Month 3, and subsequently every 3 months from Month 3 to Month 24, until the subject completes the 24-month follow-up period, experiences disease progression (PD)/relapse, initiates new anti-tumor therapy, dies, or withdraws from the study, whichever occurs first.
This description comes directly from the study's public registry record.
Juan Du, MD · 15800706091 · Juan_du@live.com
Always discuss trial participation with your own doctor first.
| Beijing GoBroad Boren Hospital | Beijing, China | Recruiting |
| The second affiliated hospital of Chongqing medical university | Chongqing, China | Not Yet Recruiting |
| Renji Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, China | Not Yet Recruiting |
| Zhengzhou Yihe Hospital | Zhengzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07493135